Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction.

European journal of heart failure·2024
Same author

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.

Journal of the American College of Cardiology·2024
Same author

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

The New England journal of medicine·2024
Same author

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.

Circulation·2024
Same author

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.

Nature medicine·2024
Same author

Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation.

JAMA cardiology·2024

Related Experiment Video

Updated: Jul 31, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K

Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement.

Barry A Borlaug1, Kavita Sharma2, Sanjiv J Shah3

  • 1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Journal of the American College of Cardiology
|May 3, 2023
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) is increasingly common. Early recognition and tailored treatments are vital for improving outcomes in this complex condition.

Keywords:
diagnosisepidemiologyheart failure with preserved ejection fractionpathophysiologytreatment

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

Related Experiment Videos

Last Updated: Jul 31, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

Area of Science:

  • Cardiology
  • Internal Medicine
  • Public Health

Background:

  • Heart failure with preserved ejection fraction (HFpEF) incidence and prevalence are rising due to aging, obesity, and cardiometabolic disorders.
  • Despite advances in understanding HFpEF pathophysiology and diagnosis, it remains under-recognized in clinical practice.
  • Effective treatments exist, highlighting the need for improved recognition and individualized care.

Purpose of the Study:

  • To provide an updated examination of HFpEF epidemiology, pathophysiology, diagnosis, and treatment.
  • To emphasize the importance of phenotyping for personalized HFpEF management.
  • To address the under-recognition of HFpEF in clinical practice.

Main Methods:

  • Review of current literature on HFpEF.
  • Analysis of epidemiological trends and risk factors.
  • Examination of pathophysiological mechanisms across cardiac, pulmonary, and extracardiac systems.
  • Evaluation of diagnostic strategies and treatment modalities.

Main Results:

  • HFpEF is a heterogeneous syndrome with increasing prevalence.
  • Under-recognition of HFpEF hinders timely and effective treatment.
  • Pathophysiological phenotyping is crucial for individualized treatment strategies.
  • Pharmacologic and lifestyle interventions show promise in improving HFpEF outcomes.

Conclusions:

  • HFpEF requires greater clinical attention due to its rising prevalence and significant morbidity.
  • Accurate diagnosis and phenotyping are essential for optimizing patient care.
  • Personalized treatment approaches, including pharmacologic and lifestyle interventions, can improve clinical status and reduce mortality in HFpEF.